Halozyme Therapeutics Inc.

NASDAQ:HALO   3:59:58 PM EDT
43.85
+0.85 (+1.98%)
Other Pre-Announcement

Halozyme Reports First Quarter 2022 Results

Published: 05/10/2022 20:12 GMT
Halozyme Therapeutics Inc. (HALO) - Halozyme Reports First Quarter 2022 Results.
Q1 Non-GAAP Earnings per Share $0.47.
Q1 Revenue Rose 32 Percent to $117.3 Million.
Q1 GAAP Earnings per Share $0.43.
Reiterate 2022 Revenue Guidance of $530 Million to $560 Million, Representing 20-26% Growth Over Reported 2021 Revenue.
Reiterate 2022 GAAP Operating Income Guidance of $350 Million to $380 Million.
Sees 2022 GAAP Diluted Earnings per Share of $1.90 to $2.05.
Non-GAAP Diluted Earnings per Share Are Expected to Be $2.05 to $2.20 in 2022.
Q1 Earnings per Share View $0.49 -- Refinitiv Ibes Data (analyst estimates).
Q1 Revenue View $128.3 Million -- Refinitiv Ibes Data (analyst estimates).